Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD4 | P21917 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8578198 | 0.85 | NOTUM (0.50) | RAB9ANPC1NOTUMSMN1; SMN2MAPT | |
| SCHEMBL8576421 | 0.82 | MEN1 (0.55) | RAB9ANPC1NOTUMSMN1; SMN2MAPT | |
| SCHEMBL3688842 | 0.82 | NOTUM (0.70) | RAB9ANPC1NOTUMSMN1; SMN2MAPT | |
| SCHEMBL103310 | 0.82 | NOTUM (0.70) | RAB9ANPC1NOTUMSMN1; SMN2MAPT | |
| SCHEMBL2906099 | 0.82 | NOTUM (0.70) | RAB9ANPC1NOTUMSMN1; SMN2MAPT | |
| SCHEMBL25010914 | 0.82 | NOTUM (0.47) | RAB9ANPC1NOTUMSMN1; SMN2MAPT | |
| SCHEMBL8288449 | 0.82 | NPC1 (0.54) | RAB9ANPC1NOTUMSMN1; SMN2MAPT | |
| SCHEMBL4981360 | 0.81 | NOTUM (0.68) | RAB9ANPC1NOTUMSMN1; SMN2MAPT | |
| SCHEMBL11484346 | 0.81 | P2RY14 (0.47) | NOTUML3MBTL1LMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL21776875 | 0.81 | NOTUM (0.68) | RAB9ANPC1NOTUMSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 PHARMA, LLC | 2021-10-14 | — | — | US | disclosed |
| WO-2021183796-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 PHARMA (US) | 2021-09-16 | — | — | WO | disclosed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| US-8883826-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-11-11 | — | — | US | disclosed |
| US-8674106-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2426115-A2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | Addex Pharma SA (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-8101637-B2 | Alkynyl derivatives as modulators of metatropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-01-24 | — | — | US | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-4203994-A | Fungicidal 3-phenyl-5-(substituted methyl)isoxazoles | ELI LILLY AND COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
| US-4109002-A | FOR PLANT FOLIAGE | ELI LILLY AND COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | RAB9A 2899/4885NPC1 1730/4885NOTUM 2510/4885 |
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | RAB9A 1458/4885NPC1 949/4885NOTUM 2492/4885 |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | RAB9A 334/4885NPC1 1167/4885NOTUM 4592/4885 |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | RAB9A 1309/4885NPC1 817/4885NOTUM 2536/4885 |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | RAB9A 1458/4885NPC1 949/4885NOTUM 2492/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | RAB9A 2257/4885NPC1 2053/4885NOTUM 4801/4885 |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | CREBBP, CREB1, EP300 | RAB9A 2899/4885NPC1 1730/4885NOTUM 2510/4885 |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | RAB9A 2899/4885NPC1 1730/4885NOTUM 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.